BIQSFP '14 (Biomarker, Imaging, & Quality of Life Studies Funding Program) COST- EFFECTIVENESS ANALYSIS (CEA) Study Evaluation Template

'14 STUDY EVALUATION TEMPLATE Cost-Effectiveness Analysis (CEA)

Reviewer's Name:
Date of Evaluation:
Concept/BIQSFP Number and Title:
Instructions for Non-NCI Evaluators: You have been asked to provide an evaluation of the cost-effectiveness analysis (CEA) study associated with the Phase 3 concept listed above. Your responsibilities as a reviewer consist of evaluating the proposed study and completing this form with your written comments by filling out the fields that follow each review criterion. A copy of the CEA Study Evaluation Guidelines which includes the Study Checklist for Phase 3 Clinical Trials with a Comparator Arm and CEA Component(s) is attached for your review.
After completing this Review please save it to a new file, attach the file to an e-mail message referencing the concept/BIQSFP number, and forward the email to the CTEP, DCP, or CCCT Program Staff responsible for sending this evaluation. Submit your response at least 3 business days preceding the concept evaluation conference call/meeting, so that all perspectives may be shared and your written comments viewed by other evaluators of this concept. You will likewise be provided access to the written comments of the other CEA evaluators.
Criteria for Review and Prioritization of CEA Studies
1. The overall value-added of pairing CEA with this clinical trial
Strengths:
Weaknesses:
2. The potential of the CEA to influence clinical practice and decision-making
Strengths:
Weaknesses:

3.	(control arm)			ervention	(s) and compar	ator
	Strengths:					
	Weaknesses:					
4.	Choice of Out	come Meas	sure(s) for th	ne analysi	S	
	Strengths:					
	Weaknesses:					
5.	The appropria	teness and	d feasibility o	of the data	a collection pla	n
	Strengths:					
	Weaknesses:					
6.	The modeling	componer	nt of the CEA	(if appro	opriate)	
	Strengths:					
	Weaknesses:					
7.	The Uncertain	ty Analysis	5			
	Strengths:					
	Weaknesses:					
8.	assigned to o	ne of the plinformation	revious crite n, the <u>streng</u>	eria over a <u>th</u> of the	r level of merit l nother. Based data presented usiasm for the s	on the
	High				Mild	
	1	2	3	4	5	

9. Please comment on the attached *BIQSFP Cost Estimate Worksheet(s)* and *Budget Justification*. Provide recommendations if needed.

It is understood that by agreeing to assist in this evaluation, you have no conflicts of interest with this concept. In addition, all unpublished information, reports, and discussions are strictly confidential.

